Cannasouth Limited (NZX:CBD) is pleased to announce that it has received its first shipment of verified cannabis medicines.
Cannasouth CEO Mark Lucas says, “This accomplishment marks the end of a near two-year process since submitting product assessments with the Medicinal Cannabis Agency.
"The differentiated formulations of our products will provide New Zealand patients and prescribers with new treatment options compared to existing products on the New Zealand market. We are confident these products offer patients and prescribers a point of difference to meet the treatment needs of a wider range of conditions.”
Navigating and establishing the supply chain for its first medicines means Cannasouth is now generating revenue from the sale of medicines in New Zealand.
A list of all medicinal cannabis products that meet the New Zealand minimum quality standard can be found here: https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicinal-cannabis-agency/medicinal-cannabis-agency-information-health-professionals/medicinal-cannabis-products-meet-minimum-quality-standard
-ENDS-
For further information visit www.cannasouth.co.nz or contact:
Mark Lucas
CEO / Executive Director
Email: [email protected]
Mobile: 021 484 649
Colin Foster
CFO / Company Secretary
Email: [email protected]
Mobile: 027 577 1498
New Zealand shares shook off weakness in overseas markets.
Three companies have been identified as being involved in the fraud, CEO says.
The past year had been one of the toughest in Spark's history, chair says.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details